Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted

• Egile Nagusiak: Lambert O (Egilea), Bandilla D (Egilea), Iyer R (Egilea), Witchey-Lakshmanan L (Egilea), Palepu N (Egilea)
• Formatua: Liburua
• Argitaratua: Dove Medical Press, 2012-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Olivier Lambert1, Dirk Bandilla1, Rupa Iyer2, Leonore Witchey-Lakshmanan3, Nagesh Palepu41Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 2TPM Laboratories Inc, Cherry Hill, NJ, USA; 3Pharma CMC/IP, Piscataway, NJ, USA; 4SciDose LLC, Amherst, MA, USAPurpose: Epoprostenol, used for the treatmen...